Neutral
NovoCure (NVCR) Is Up 8.1% After TRIDENT Shows No Survival Gain From Earlier TTFields Start
NovoCure (NVCR) shares rose 8.1% after its Phase 3 TRIDENT trial revealed that starting Tumor Treating Fields (TTFields) earlier with chemoradiation d...